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Abstract 
Current methods for investigation of receptor - ligand interactions in drug discovery are based on 
three-dimensional complementarity of receptor and ligand surfaces, and they include pharmacophore 
modelling, QSAR, molecular docking etc. Those methods only consider short-range molecular 
interactions (distances <5Å), and not include long-range interactions (distances >5Å) which are 
essential for kinetic of biochemical reactions because they influence the number of productive 
collisions between interacting molecules. Previously was shown that the electron-ion interaction 
potential (EIIP) represents the physical property which determines the long-range properties of 
biological molecules. This molecular descriptor served as a base for development of the informational 
spectrum method (ISM), a virtual spectroscopy method for investigation of protein-protein 
interactions. In this paper, we proposed a new approach to treat small molecules as linear entities, 
allowing study of the small molecule - protein interaction by ISM. We analyzed here 21 sets of KEGG 
drug-protein interactions and showed that this new approach allows an efficient discrimination 
between biologically active and inactive ligands, and consistence with AA regions of their binding 
site on the target protein.   
Keywords:   ISM method, CIS spectra, small molecules, smiles notation, target-ligand recognition, 
protein target regions 
1. Introduction  
Receptor - ligand interactions in biological systems are considered as any non-covalent interactions 
between protein and small molecule, antibody - antigen, protein - peptide, enzyme - substrate etc. 
They play key role all in biological processes in living cell, for they mediate the whole signal paths. 
Therefore, the research of those phenomena is highly important as well from biophysical view, to 
chemical, pharmacological and medicinal. The foundations of modern understanding of receptor-
ligand interactions are based on their short contacts and surface complementarity (short-range 
molecular interactions), where specific non-covalent interactions form and trigger the important 
processes in cell. Modern drug design methods that deal with receptor-ligand interactions are mostly 
oriented towards three-dimensional (3D) approaches, based on direct interactions of ligand and 
receptor molecules. They are divided into two groups: structure-based and ligand-based, depending 
if the structure of receptor is known or not, respectively. Approaches such as 3D QSAR and 
pharmacophore modelling belong to ligand-based, while molecular docking and molecular dynamics 
belong to structure-based drug design methods [Silverman and Holladay al, 2014]. They are all 
founded on Emil Fisher’s [Fischer E., 1894] theory, where interactions between ligand molecule and 
target receptor are based on complementarity of surfaces between receptor and ligand molecules. 
They occur at distances lower than 5Å and, as stated, represent current concept of short range 
intermolecular interactions. According to collision theory, thermal motions achieve first contact 
between interacting molecules accidentally and such generated interactions are considered as short-
range intermolecular contacts. However, there are strong disagreements between theory and 
experimental measurements. Comparison of theoretically calculated rate constants and experimental 
data yields prior values lower by several orders of magnitude [Smoluchowski, 1916; Northrup and 
Erickson, 1992]. In order to overcome those disagreements, several models were proposed, such as 
reducing the dimensionality of diffusion [Wiegel and DeLisi, 1982; McCloskey and Poo , 1986; 
Peters, 2005], protein association based on hydrodynamic steering [Brune et al, 1994], desolvation-
mediated protein-protein binding  [Camacho et al, 2000], etc. One of the most acceptable 
considerations for this issue was reported by the physicist Frönlich [Fröhlich, 1968; Fröhlich; 1970, 
Fröhlich, 1975]. From a very general theoretical consideration, he acclaimed that biomolecules are 
capable to excite dipole vibrations. Based on that vibrations, in polar medium biomolecules mutually 
develop attractive long - range forces, characterized by specific frequency. Because of common 
vibration frequencies, interacting molecules produce larger number of effective collisions than by 
random encounter. Long-range intermolecular interactions play key role in receptor-ligand molecular 
recognition and determine processes in vivo and overall biological activities. Complementary to the 
structure based methods, long range molecular interactions are important on distances above 1000 Å 
[Leckband and Israelachvili, 2001]. Based on Fröhlich’s theory [Fröhlich, 1968; Fröhlich; 1970, 
Fröhlich, 1975] and general pseudopotential model [Veljkovic V. and Slavic I., 1972], Electron Ion 
Interaction Potential (EIIP) descriptor [Veljkovic V., 1980] was developed for small molecules. The 
EIIP descriptor considers valence electrons on small molecule, and based on molecular formula, 
calculates two values, the average quasi valence number and EIIP value. Both values are considered 
as two-dimensional molecular descriptor, which can be used to cluster similar molecules by means 
of targeting the same receptor. However, the EIIP descriptor is limited to small molecules and 
development of approaches for larger molecules, mostly proteins, was demanded. As extension of 
EIIP descriptor methodology, the Informational spectrum method (ISM)  [Veljkovic et al, 1985], a 
virtual spectroscopy method was developed. In ISM method, each aminoacid (AA) reside in protein 
sequence is coded with corresponding EIIP value, and corresponding data graph EIIP value vs. ordinal 
number of AA is constructed. Applying the Discrete Fourier Transformation on this data one obtains 
corresponding amplitudes and frequencies as output data, which is used to construct ISM spectrum. 
According to ISM [Veljkovic et al, 1985], two biological macromolecules (proteins) interact if 
multiplication of their individual ISM spectra (consensus informational spectrum, CIS) yield one or 
more common frequencies, which determines aminoacid regions in both proteins, responsible for 
molecular recognition on long distances. Thus, one can explain whether two proteins interact or not, 
or it can be used for prediction and peptide design for specific target. The ISM method has been fully 
developed for proteins and nucleic acids [Veljkovic et al, 1985] , while for small molecules, candidate 
prediction for a specific target is limited to their selection according to ranges of EIIP descriptor 
values, determined from molecular formulas of known target ligands. Using EIIP descriptor one can 
select small molecule candidates from numerous databases under criteria if they fall in appropriate 
value range. This is important in design and selection of new drug candidates, and it can be considered 
as initial step in drug design, because reducing the number of potential candidates saves 
computational time and effort in 3D structure based discovery processes coupled in one joint long-
range-short-range virtual screening protocol. It is also useful in drug re-purposing discovery, because 
drugs multi-targeting can be predicted [Veljkovic et al, 2015]. However, a question on small molecule 
raises by means of improvement of EIIP method and possible applying of ISM method. Therefore, 
for the first time, we propose a new approach to treat molecules as quasi-linear entities, analogous to 
peptides and application of ISM method in order to predict potential candidates for specific target. 
We based our research on GPCR drugs of Golden dataset and used aminoacid sequences of 
corresponding receptors. The ISM treatment of small molecules as pseudopeptides shown consistency 
with treatment of peptides, yielding specific binding regions in GPCR. Physically, we showed that 
absence of 3D structure information in small molecules is irrelevant for the estimation of their 
targeting to specific receptor protein.  
2. Methods 
2.1 Linear notation of the small molecule 
The idea of linear notation of the small molecule dates from 1988 and was originally reported by 
Anderson and Weininger [Anderson et al, 1987; Weininger, 1988], by means of line notation 
simplified molecular input line entry system (SMILES). The idea is based on a fact that each atomic 
group in linear or chain molecule can be written as one letter, denoting its type. Thus, we have alkyl 
groups, aromatic carbon atoms, halogen, hydroxyl group etc. Based on that idea, analogously to 
peptide, a small molecule can be written as sequence of atomic groups, with specific labeling. For 
instance, structural formula of simple hydrocarbon pentane is: 
CH3CH2CH2CH2CH3  (2.1.1) 
The corresponding smiles notation is: 
CCCCC (2.1.2) 
If we denote CH3 group in (2.1.1) as P (primary carbon atom) and CH2 group as S (for secondary 
carbon atom), and if we use the sequence of (2.1.2) to apply those notations on pentane molecule, we 
obtain: 
PSSSP (2.1.3) 
There, we wrote a pentane molecule in a sequence. Similar cam be derived for chain molecules or 
those including rings. For instance, smile notation of simple chain molecule of 2-methylbutane is 
CC(C)CC (2.1.4) 
where (C) denotes methyl group substituent on second carbon atom. If we label C atoms in (2.1.4), 
we obtain: 
𝐶1𝐶2(𝐶)3𝐶4𝐶5 (2.1.5) 
Where atom superscripts denote their ordinal numbers. Thus, we can write molecule (2.1.5)  as: 
PTPSS (2.1.6) 
Where T signifies tertiary carbon atom. In case of ring-containing molecules, which is actually the 
vast majority of chemical compounds, for instance the molecule 3-(pyperidin-4-yl)phenol, 
corresponding smiles notation is: 
Oc1cc(ccc1)C2CCNCC2 (2.1.7) 
Using the smiles sequence for pseudopeptide generation, if we denote NH group as Y, quaternary 
carbon atom as Q and OH group as A, we obtain: 
AQTQTTTTSSYSS (2.1.8) 
Thus, we can use smiles to write small molecules in one dimension and, using specific notations for 
each atomic group, we can write it as pseudopeptide. The very first question that arises from and 
notations (2.1.7) and (2.1.8) is the absence of three-dimensional information of the molecule, i.e. 
parenthesis from formula (2.1.7). However, through this paper we will show that loss of a molecular 
3D structural information does not affect physical interpretation of a method proposed here. 
2.2 Electron – ion interaction potential and ISM method 
The concept of electron-ion interaction potential (EIIP) is derived from the “general model 
pseudopotential” and assumes that number of valence electrons and their main energy term of the 
valence determine long-range properties of molecule. The EIIP descriptors are easily calculated using 
following formulas: 
𝑍∗ = ∑ 𝑛𝑖𝑍𝑖/𝑁
𝑚
𝑖=1   (2.2.1) 
 𝐸𝐼𝐼𝑃 = 0.25𝑍∗ sin(1.04𝜋𝑍∗) /2𝜋 (2.2.2) 
 
Where: 
 i, Type of the chemical element; 
 Z, Valence of the i-th chemical element; 
 n, Number of the i-th chemical element atoms in the compound; 
 m, Number of types of chemical elements in the compound; 
 N, total number of atoms. 
The EIIP values calculated according to the Equation (2.2.2) are in Rydbergs (Ry = 13.6 eV). As 
stated in Introduction, the EIIP descriptor is fully developed for small organic molecules. Based on 
EIIP descriptors, ranges of their values are borders of 2D chemical space where molecules that target 
specific receptor belong. There is a strong connection between EIIP and Z* molecular descriptors of 
small molecules and their biological activities (carcinogenisity, antibiotic activity, antiviral activity, 
toxicity, etc.) [Veljkovic et al, 2016]. However, EIIP descriptor holds only for small organic 
molecules, and for larger (peptides for instance) the different method is demanded. As an its 
extension, Informational Spectroscopy Method (ISM) was developed. The ISM is a virtual 
spectroscopy method for calculation of the long-range properties of biological macromolecules. It is 
based on a model that assigns to each amino acid a value of  electron-ion interaction potential (EIIP) 
descriptor. [Veljkovic et al, 1985] 
ISM method consists in three basic steps: 
1. Transformation of protein primary sequence into an array of numbers representing EIIP of each 
AA residue. 
2. Conversion of numerical array by fast Fourier Transformation into information spectrum, which 
yields dominant frequency peaks of the molecule 
3. Consensus Information Spectrum (CIS) analysis between ISM spectra of two interacting molecules, 
which yields functional locus of the interaction of two molecules. 
Frequencies of peaks in CIS are common for interacting biomolecules. The measure of their 
similarity to individual IS of interacting molecules is signal-to-noise ration (S/N), the ratio between 
the signal intensity in IS and the CIS spectra. The method has been successful in identification of 
functional protein domains representing candidate therapeutic targets for anti-HIV drugs [Veljkovic 
et al, 2007], anthrax [Doliana et al, 2008], and human influenza viruses [Veljkovic et al, 2009a; 
Veljkovic et al, 2009b; Perovic et al, 2013]. and is used used in more than 100 research centers 
worldwide [Veljkovic et al, 2011]. Analogously to EIIP values of AA for ISM method, we isolated 
from smile notation atomic groups and calculated corresponding EIIP values, which would be used 
in calculation of small molecule ISM spectra, and they are presented in Table 1.  
Table 1. Atomic groups with corresponding pseudoaminoacid labels and EIIP values. Note that 
duplicate values are due to different element or atomic group representation in smiles.
Atomic 
group  in 
smiles 
Label for 
ISM 
EIIP value 
2H H 0.004987 
3H H 0.004987 
As As 0.56762 
C C 0.076673 
CH CH 0.094603 
CH2 CH2 0.01979 
CH3 CH3 0.03731 
11CH3 11CH3 0.03731 
N N 0.116936 
NH NH 0.043942 
NH2 NH2 0.090387 
NH3 NH3 0.01979 
O O 0.163424 
OH OH 0.126007 
OH2 OH2 0.06933 
S S 0.163424 
SH SH 0.126007 
cH CH 0.094603 
n N 0.116936 
nH NH 0.043942 
B B 0.043942 
BH BH 0.01979 
BH2 BH2 0.049281 
Au Au 0.429924 
Hg Hg 0.476523 
Sn Sn 0.547176 
Se Se 0.576031 
se Se 0.576031 
P P 0.116936 
BH3 BH3 0.058626 
Si Si 0.076673 
PH PH 0.043941 
I I 0.004986 
125I 125I 0.004986 
C=O=O COO 0.20993 
N=C=S NCS 0.116936 
S=C=N SCN 0.116936 
S=O=O SOO 0.163424 
O=N=O ONO 0.074149 
N=O=O NOO 0.074149 
N#N=N NNN 0.116936 
C=N CN 0.151176 
N=C NC 0.151176 
C=O CO 0.116936 
O=C OC 0.116936 
c=O CO 0.116936 
O=c OC 0.116936 
C=S CS 0.116936 
c=S CS 0.116936 
F=O FO 0.126007 
I=O IO 0.126007 
N=O NO 0.168618 
P=O PO 0.168618 
P=S PS 0.168618 
C#N CN 0.151176 
N#C NC 0.151176 
Br Br 0.004987 
Cl Cl 0.004987 
Sc Sc 0.043941 
Sn Sn 0.547176 
Se Se 0.576031 
se Se 0.576031 
C C 0.076673 
F F 0.004987 
I I 0.004987 
N N 0.116936 
O O 0.163424 
P P 0.116936 
S S 0.163424 
c C 0.076673 
n N 0.116936 
o O 0.163424 
s S 0.163424 
B B 0.043942 
PH PH 0.043941 
 
 
2.3 Small molecule databases and protein sequences 
For our research, we used Golden dataset receptor-drug matrix, the standard in current bioinformatics 
[Yamanishi et al, 2008, Wolf & Grünewald 2015, Vagmita & Li 2012, Rosenbaum et al 2014, Carrieri 
et al 2001, Scheer et al 1996, Evers & Klabunde 2005, Fraser et al 1989]. However, we limited only 
to GPCR receptor-drug data, consisting of 222 KEGG drugs and 95 receptors. The number of drugs 
showing activity per receptor in matrix varies from 1 to 35, and we had to limit number of receptors 
to arbitrary value. We selected only the ones with 10 and more drugs per receptor, yielding 21 
receptor. From this matrix, we constructed 21 positive and 21 negative training sets, selecting 10 
random drugs per protein of each class. ISM spectra of selected proteins and drugs were calculated 
using internal laboratory software. Drug spectra of each set were multiplied with spectra of receptor 
in order to obtain characteristic frequencies. Protein AA regions were calculated on a basis of 
characteristic frequencies using laboratory software. Data on binding site AAs for each protein were 
taken from point mutation experiments literature [Shi L & Javitch 2002]. The aminoacid sequences 
of proteins, as well as drug structures were downloaded from KEGG database [Kanehisa et al 2017, 
Kanehisa et al  2016, Kanehisa & Goto 2000]. The drug structural mol files were converted to smiles 
notation. Explicit hydrogen atoms were added to smiles using Open Babel program [O'Boyle et al, 
2011], followed by conversion into canonical form. AQVN and EIIP descriptors values of drugs were 
also calculated. All data can be found in Supplementary material 1.  
3. Results and discussion 
The results of ISM spectra multiplications and determination of corresponding AA regions 
in receptors are presented in Table 2.  
Table 2. Major ISM frequencies of drug-receptor CIS spectra of 21 GPCR, with corresponding protein 
domains – positive sets 
No 
Receptor 
KEGG 
code 
Receptor name 
Major ISM 
frequency  
Major 
ISM 
frequency 
amplitude 
for 
positive 
set 
Binding 
site AAs 
ISM 
frequency 
corresponding 
AA region 
Window 
size 
1 hsa:146 
Alpha-1D 
adrenergic receptor 
0.0625 5.56E-13 
170 252 
256 174 
383 379 
375 229 
163 240 
358 383 
277 - 292 16 
2 hsa:147 
Alpha-1B 
adrenergic receptor 
0.0546875 1.23E-12 
63 91 344 
348 142 
143 293 
161- 225 
128, but 
shortened 
to 65 
3 hsa:148 
Alpha-1A 
adrenergic receptor 
0.0625 1.22E-13 
 86  313 
106 184 
192- 207 16 
4 hsa:150 
Alpha-2A 
adrenergic receptor 
0.0546875 1.07E-13 
197 200 
201 204 
412 
142 - 206 
128, but 
shortened 
to 65 
5 hsa:151 
Alpha-2B 
adrenergic receptor 
0.048828 1.21E-14 - N/A   
6 hsa:152 
Alpha-2C 
adrenergic receptor 
0.4375 3.73E-15 
210 213 
214 217 
424 
(analogous 
residues to 
Alpha-2A 
adrenergic 
receptor) 
191 - 222 32 
7 hsa:153 
Beta-1 adrenergic 
receptor 
0.039 2.26E-14  - N/A   
8 hsa:154 
Beta-2 adrenergic 
receptor 
0.0429 2.11E-14  - N/A   
9 hsa:155 0.039 3.51E-14 - N/A   
Beta-3 adrenergic 
receptor 
10 hsa:1128 
Muscarinic 
acetylcholine 
receptor M1 
0.40625 1.03E-14 
71  99 101 
102 105 
106 109 
113 188 
189 190 
192 196 
381 382 
400 404 
407  
172 
32 
203 
11 hsa:1129 
Muscarinic 
acetylcholine 
receptor M2 
0.0605 1.09E-14 - N/A   
12 hsa:1131 
Muscarinic 
acetylcholine 
receptor M3 
0.0546875 1.87E-13 
148 192 
201 231 
234 242  
503 506 
507 529 
533 
102 
 64 
166 
13 hsa:1812 
D(1A) dopamine 
receptor 
0.0605 4.55E-14 - N/A   
14 hsa:1813 
D(2) dopamine 
receptor 
0.328125 5.93E-14 
80 91 115 
118 160 
169 171 
189 193 
194 197 
198 201 
386 387 
389 394 
417 418 
419 391 
420  
90 
64 
153 
15 hsa:1814 
D(3) dopamine 
receptor 
0.0625 8.07E-13 
114 349 
369 
113 128   16 
16 hsa:3269 
Histamine H1 
receptor 
0.3339 1.37E-13 - N/A   
17 hsa:3351 
5-
hydroxytryptamine-
1B receptor 
0.2929688 1.15E-13 - N/A   
18 hsa:3352 
5-
hydroxytryptamine-
1D receptor 
0.2871094 1.65E-13 - N/A   
19 hsa:3356 
5-
hydroxytryptamine-
2A receptor 
0.3417 8.68E-15 -  N/A   
20 hsa:3358 
5-
hydroxytryptamine-
2C receptor 
0.2851563 9.70E-14 - N/A   
21 hsa:3577 
High affinity 
interleukin-8 
receptor A 
0.0820313 6.93E-17 - N/A   
 
During interpretation of results, we had to apply a few conditions. Regarding frequency 
values, not all are meaningful to interpret, because their value determines the “window size” (smallest 
number of AA residues sized 2n, where n  N). Therefore, the frequency value is dividable with 
1/window size value. For example, the inverse value of window size 16 is 0.0625 and for instance, 
frequency 0.0625 is dividable with it. Further, for example, inverse value of window size 32 is 
0.03125 and frequency 0.4375 is dividable with it etc. Regarding window size, we presented results 
only for cases where it does not exceed 128 residues, because for average size of 300-400 AA 
residues, a 128 AA domain occupies almost 1/3 of protein, which makes protein – ligand targeting 
specificity lost.  
Our results show good agreement with experimentally determined binding site AAs [Shi & 
Javitch, 2002, Wolf & Grünewald 2015, Vagmita & Li 2012, Rosenbaum et al 2014, Carrieri et al 
2001, Scheer et al 1996, Evers & Klabunde 2005, Fraser et al 1989], regarding positive sets of drugs. 
The best specificity is reported in case of Alpha-1D adrenergic receptor and Alpha-1A adrenergic 
receptor. The window size is only 16, and corresponding domains are in agreement with 
experimentally determined binding site residues by point mutations. Somewhat wider window size 
(32) is reported in case of Alpha-2C adrenergic receptor and Muscarinic acetylcholine receptor M1, 
even wider in case of D(2) dopamine receptor (64), while boundary cases are reported with Alpha-
1B adrenergic receptor and Alpha-2A adrenergic receptor (65). This actually corresponds to window 
size 128, but size 65 can be considered as “narrowed”. Comprehensibly, the wider AA range brings 
higher tolerance for domain interpretation. However, in all cases the reported domains contain a 
number of binding site AA residues. In the rest of the cases, major ISM frequency origins from AA 
domains, which are not interpretable with sufficient specificity, i.e. window size is too wide. 
Regarding negative sets, their results differ from positive in both major ISM frequencies and 
corresponding amplitudes. The ISM frequencies are non-specific for the most of receptors (Table 3), 
and corresponding amplitudes are a few orders of magnitude lower from corresponding positive sets 
(Tables 2-3). However, there are exceptions in cases of High affinity interleukin-8 receptor A, and 5-
hydroxytryptamine-2A receptor, where are major ISM frequency amplitudes higher in negative sets 
than positive. In addition, there are two false positive cases (Alpha-2B adrenergic receptor and 
Histamine H1 receptor, Table 3). 
Table 3. Major ISM frequencies of drug-receptor CIS spectra of 21 GPCR, with corresponding protein 
domains – negative sets 
No 
Receptor 
KEGG 
code 
Receptor name 
Major ISM 
frequency  
Major 
ISM 
frequency 
amplitude 
for 
negative 
set 
ISM 
frequency 
corresponding 
AA region 
Window 
size 
1 hsa:146 
Alpha-1D 
adrenergic receptor 
0.1210938 1.80E-16 N/A   
2 hsa:147 
Alpha-1B 
adrenergic receptor 
0.28125 1.58E-15 N/A   
3 hsa:148 
Alpha-1A 
adrenergic receptor 
0.2734375 1.24E-15 N/A   
4 hsa:150 
Alpha-2A 
adrenergic receptor 
0.0957031 1.06E-15 N/A   
5 hsa:151 
Alpha-2B 
adrenergic receptor 
0.0625 7.24E-11 68 83 16 
6 hsa:152 
Alpha-2C 
adrenergic receptor 
0.0449219 2.29E-14 N/A   
7 hsa:153 
Beta-1 adrenergic 
receptor 
0.1425781 1.91E-16 N/A   
8 hsa:154 
Beta-2 adrenergic 
receptor 
0.1113281 2.37E-14 N/A   
9 hsa:155 
Beta-3 adrenergic 
receptor 
0.0507813 1.27E-13 N/A   
10 hsa:1128 
Muscarinic 
acetylcholine 
receptor M1 
0.0585938 3.40E-12 N/A   
11 hsa:1129 
Muscarinic 
acetylcholine 
receptor M2 
0.2207031 3.03E-16 N/A   
12 hsa:1131 
Muscarinic 
acetylcholine 
receptor M3 
0.1386719 6.90E-16 N/A   
13 hsa:1812 
D(1A) dopamine 
receptor 
0.1171875 1.86E-14 N/A   
14 hsa:1813 
D(2) dopamine 
receptor 
0.1210938 2.41E-15 N/A   
15 hsa:1814 
D(3) dopamine 
receptor 
0.2285156 1.92E-16 N/A   
16 hsa:3269 
Histamine H1 
receptor 
0.078125 5.54E-16 102 165 64 
17 hsa:3351 
5-
hydroxytryptamine-
1B receptor 
0.0449219 7.99E-15 N/A   
18 hsa:3352 
5-
hydroxytryptamine-
1D receptor 
0.1113281 1.87E-15 N/A   
19 hsa:3356 
5-
hydroxytryptamine 
-2A receptor 
0.1113281 6.29E-14 N/A   
20 hsa:3358 
5-
hydroxytryptamine 
-2C receptor 
0.0449219 4.70E-17 N/A   
21 hsa:3577 
High affinity 
interleukin-8 
receptor A 
0.0429688 2.65E-14 N/A   
 
All spectra of receptors, their positive and negative sets CIS spectra and corresponding AA 
regions of receptor are given in Supplementary material.  
4. Conclusion 
In this paper, we introduced a new approach in bioinformatics treatment of small molecules and their 
classification on active and inactive compounds towards specific target. We acquired standard linear 
notation of small their structure - SMILES and converted atomic groups into pseudoaminoacid 
residues. Small molecule in such notation can be treated as peptide, and therefore ISM method can 
be applied. Its spectra can be multiplied with spectra of protein receptor to obtain proper CIS. 
Individual CIS spectra of sets active and inactive compounds and corresponding receptor differ in 
frequency and amplitude values. Their interpretation by means of the receptor AA sequence yields 
specific regions, which contain crucial aminoacid residues for ligand-target recognition, based on 
long-range intermolecular interactions.  The very important information that can be extracted from 
ligand CIS spectra is AA region of the binding site in corresponding receptor. However, there are 
notable limitations of this method, which are probably due to drug sets and statistical probabilities 
regarding formation of proper reliable set.  
With further development and introduction of advanced data analysis, such as machine learning we 
believe that those deficiencies will be overcome. This new approach brings new possibilities by 
means of developing new techniques in ligand classification and selection of new candidates for 
specific target. 
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Appendix. Supplementary Material 
Receptor ISM spectra, CIS spectra of positive set, AA  region and CIS spectra of negative set, 
respectively, with positive and negative sets: 
hsa:146 alpha-1d adrenergic receptor 
 
  
 hsa:147 alpha-1b adrenergic receptor 
 
  
 hsa:148 alpha-1a adrenergic receptor 
 
  
 hsa:150 alpha-2a adrenergic receptor 
 
  
 hsa:151 alpha-2b adrenergic receptor 
 
  
hsa:152 alpha-2c adrenergic receptor 
  
  
hsa:153 beta-1 adrenergic receptor 
  
  
hsa:154 beta-2 adrenergic receptor 
 
 hsa:155 beta-3 adrenergic receptor 
 
  
hsa 1128 muscarinic acetylcholine receptor m1 
  
  
 
hsa 1129 muscarinic acetylcholine receptor m2 
  
 hsa 1131 muscarinic acetylcholine receptor m3 
 
  
 hsa 1812  d(1a) dopamine receptor 
 
  
hsa 1813 d(2) dopamine receptor 
  
  
hsa 1814 d(3) dopamine receptor 
  
  
hsa:3269 histamine h1 receptor 
  
 hsa:3351 5-hydroxytryptamine receptor 1b 
 
  
 
 
 
hsa:3352 5-hydroxytryptamine receptor 1d 
 
 
 hsa:3356 5-hydroxytryptamine receptor 2a 
 
  
 
 
hsa:3358 5-hydroxytryptamine receptor 2c 
 
 
 hsa:3577 high affinity interleukin-8 receptor a 
 
  
 
hsa 146 
Positive 
set KEGG Drug 
1 D00255 
2 D00281 
3 D00283 
4 D00426 
5 D00437 
6 D00454 
7 D00509 
8 D00513 
9 D00604 
10 D00607 
  
  
Negative 
set  
1 D00049 
2 D00059 
3 D00079 
4 D00094 
5 D00095 
6 D00106 
7 D00110 
8 D00113 
9 D00136 
10 D00139 
 
 
hsa 147 
Positive 
set KEGG Drug 
1 D00255 
2 D00281 
3 D00283 
4 D00426 
5 D00437 
6 D00454 
7 D00509 
8 D00513 
9 D00607 
10 D00609 
  
  
Negative 
set  
1 D00440 
2 D00443 
3 D00480 
4 D00493 
5 D00498 
6 D00514 
7 D00520 
8 D00521 
9 D00522 
10 D00523 
 
hsa 148 
Positive 
set KEGG Drug 
1 D00095 
2 D00255 
3 D00281 
4 D00283 
5 D00426 
6 D00437 
7 D00454 
8 D00494 
9 D00503 
10 D00509 
  
  
Negative set 
1 D00440 
2 D00443 
3 D00480 
4 D00498 
5 D00499 
6 D00514 
7 D00520 
8 D00521 
9 D00522 
10 D00523 
 
hsa 150 
Positive 
set KEGG Drug 
1 D00136 
2 D00255 
3 D00270 
4 D00281 
5 D00283 
6 D00332 
7 D00437 
8 D00454 
9 D00509 
10 D00513 
  
  
Negative set 
1 D00394 
2 D00400 
3 D00410 
4 D00422 
5 D00440 
6 D00443 
7 D00480 
8 D00498 
9 D00499 
10 D00520 
 
hsa 151 
Positive 
set KEGG Drug 
1 D00136 
2 D00255 
3 D00270 
4 D00281 
5 D00283 
6 D00437 
7 D00454 
8 D00509 
9 D00513 
10 D00563 
  
  
Negative set 
1 D00760 
2 D00765 
3 D00769 
4 D00780 
5 D00845 
6 D00954 
7 D00965 
8 D00987 
9 D01071 
10 D01103 
 
hsa 152 
Positive 
set KEGG Drug 
1 D00281 
2 D00509 
3 D00604 
4 D00606 
5 D00607 
6 D00609 
7 D00613 
8 D00996 
9 D01022 
10 D01603 
  
  
Negative set 
1 D01332 
2 D01346 
3 D01386 
4 D01441 
5 D01462 
6 D01652 
7 D01692 
8 D01699 
9 D01745 
10 D01782 
 
hsa 153 
Positive 
set KEGG Drug 
1 D00095 
2 D00235 
3 D00255 
4 D00432 
5 D00437 
6 D00454 
7 D00483 
8 D00513 
9 D00598 
10 D00601 
  
  
Negative set 
1 D00498 
2 D00499 
3 D00514 
4 D00520 
5 D00521 
6 D00522 
7 D00523 
8 D00525 
9 D00542 
10 D00559 
 
hsa 154 
Positive 
set KEGG Drug 
1 D00095 
2 D00235 
3 D00255 
4 D00432 
5 D00437 
6 D00454 
7 D00483 
8 D00513 
9 D00598 
10 D00601 
  
  
Negative set 
1 D00301 
2 D00306 
3 D00336 
4 D00356 
5 D00364 
6 D00371 
7 D00380 
8 D00394 
9 D00400 
10 D00410 
 
hsa 155 
Positive 
set 
KEGG 
Drug 
1 D00255 
2 D00432 
3 D00437  
4 D00454 
5 D00483 
6 D00513 
7 D00996 
8 D01390 
9 D01454 
10 D02066 
  
  
Negative set 
1 D00665 
2 D00666 
3 D00673 
4 D00674 
5 D00675 
6 D00676 
7 D00682 
8 D00683 
9 D00684 
10 D00687 
 
 
hsa 1128 
Positive 
set KEGG Drug 
1 D00113 
2 D00232 
3 D00274 
4 D00283 
5 D00397 
6 D00454 
7 D00465 
8 D00494 
9 D00524 
10 D00525 
 D00540 
  
Negative set 
1 D00422 
2 D00674 
3 D00682 
4 D00683 
5 D00684 
6 D00687 
7 D00688 
8 D00760 
9 D00765 
10 D00769 
 
hsa 1129 
Positive 
set KEGG Drug 
1 D00113 
2 D00397 
3 D00454 
4 D00494 
5 D01871 
6 D02070 
7 D02354 
8 D02361 
9 D00524 
10 D00540 
  
  
Negative set 
1 D01745 
2 D01782 
3 D01828 
4 D01891 
5 D01925 
6 D01964 
7 D01994 
8 D02007 
9 D02082 
10 D02147 
 
hsa 1131 
Positive 
set KEGG Drug 
1 D00113 
2 D00232 
3 D00454 
4 D00494 
5 D01699 
6 D01871 
7 D02070 
8 D02354 
9 D02361 
10 D03621 
  
  
Negative set 
1 D00443 
2 D00480 
3 D00498 
4 D00499 
5 D00514 
6 D00520 
7 D00521 
8 D00522 
9 D00523 
10 D00525 
 
hsa 1812 
Positive 
set KEGG Drug 
1 D00059 
2 D00110 
3 D00270 
4 D00283 
5 D00454 
6 D00493 
7 D00503 
8 D00560 
9 D00613 
10 D00790 
  
  
Negative set 
1 D00241 
2 D00295 
3 D00301 
4 D00306 
5 D00336 
6 D00356 
7 D00364 
8 D00371 
9 D00380 
10 D00394 
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